Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Lyra Therapeutics, Inc. (LYRA)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 19%. Looking ahead, revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 29% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 6 warning signs with Lyra Therapeutics (at least 1 which is concerning) , and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodol
Show less
Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYRA alerts
High impacting Lyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LYRA
News
- Incendia Therapeutics Appoints Bradford Smith as Chief Financial OfficerBusiness Wire
- Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisGlobeNewswire
- Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsGlobeNewswire
LYRA
Sec Filings
- 12/16/24 - Form SC
- 12/13/24 - Form 8-K
- 12/11/24 - Form 4
- LYRA's page on the SEC website